CNS Pharmaceuticals (CNSP) Investor presentation summary

Strategic transformation and leadership

• New executive team with deep expertise in neurology, oncology, and rare diseases is leading a strategic pivot to reposition for long-term growth.

• Leadership includes proven track records in scaling organizations, advancing clinical programs, and executing strategic transactions.

• Lean operating structure and disciplined capital allocation are central to the new strategy.

Focus on high-value neurology and oncology markets

• Refocused on neurology and oncology, targeting large, growing markets with significant unmet needs and strong commercial viability.

• Neurology and oncology together represent nearly 50% of investment and deal flow in the sector.

• Oncology therapeutics market projected to exceed $400B over the next decade; neurology market exceeds $138B.

Asset acquisition and development strategy

• Formal asset search underway, targeting novel, differentiated clinical-stage programs with clear biological rationale and near-term catalysts.

• Diligence process includes market assessment, differentiation analysis, and risk mapping to identify assets with strong value creation potential.

• Legacy programs are being positioned for out-licensing to unlock non-dilutive upside.